BACKGROUND MicroRNA-223 (miR-223) is a hematopoietic lineage cell-specific microRNA. However, a significant
atherosclerosis. However, the molecular mechanisms responsible for atherogenesis induced by blood cells and any related new therapeutic targets remain to be defined (1) .
Micro-ribonucleic acids (miRNAs) are a class of endogenous, small, noncoding RNAs that directly regulate >30% of genes in a cell (2, 3) . Once thought to exist only within cells, recent studies from our groups and others have demonstrated that miRNAs can be exported from cells (4) (5) (6) . MicroRNAs are found in many bodily fluids, including circulating blood and urine. Moreover, extracellular miRNAs are stable due to binding with microparticles. These extracellular miRNAs may enter into other tissues and cells to serve as novel cell-to-cell communicators (7) .
MicroRNA-223 is a hematopoietic lineage, cellspecific miRNA. Recent studies have revealed that miR-223 is nearly exclusively expressed in hematopoietic cells at bone marrow and in bone marrowderived blood cells, mainly in blood platelets and leukocytes, and has a low level in red blood cells (8) .
Although vascular cells should have no endogenous miR-223 expression, a significant amount of miR-223 has been identified in normal vascular walls, as has been demonstrated previously (9) .
We hypothesized that miR-223 could be secreted 
METHODS
VSMCs from the aortas of male Sprague-Dawley rats were cultured with Dulbecco's modified Eagle's medium containing 10% fetal bovine serum. For the platelet study, mouse (C57BL/6) platelets were isolated using platelet-rich plasma and the gel filtration method (10) . For the leukocyte study, mouse monocytes from blood were used and isolated as previously described (11) . We also used human monocytic cell line THP-1 cells (ATCC, Manassas, Virginia).
Microparticles from serum were isolated by ultracentrifugation (4, 5) . RNAs were isolated with a reagent (TRIzol, Life Technologies, Carlsbad, California) (5, 9) . Levels of miRNAs and messenger RNAs were determined by real-time reverse transcriptionpolymerase chain reaction (qRT-PCR). The absolute quantification of a miRNA was on the basis of qRT-PCR and a standard curve using a series of concentrations of synthesized mature miRNA (4, 5) , which were expressed as picomoles per liter, copies per cell, or copies per 15-pg tissue RNA.
The profiles of miRNAs in serum, blood cells (platelets and leukocytes), and blood microparticles were performed using Rodent
MicroRNA low-density array, whereas human miRNA profiling was performed using a human low-density array (both TaqMan, Life Technologies).
The expression of miR-223 was down-regulated by its inhibitor and up-regulated via its mimics.
Culture medium was collected before and after 12 h of THP-1 macrophage culture, and miR-223 levels in the collected medium were determined. In addition, the collected medium after 12 h of THP-1 macrophage culture was added to the cultured medium of VSMCs. After 12 h, levels of miR-223 in VSMCs were determined.
THP-1 macrophages were seeded in the upper chamber of a co-culture system and then transfected with Cy3-marked miR-223. VSMCs were added into the lower chamber. Secretion of Cy3-marked miR-223
and its ability to enter into VSMCs were monitored by fluorescence microscopy.
In vivo, mice miR-223 expression was knocked down by the locked nucleic acid miRNA inhibitor for miR-223 (LN-anti-miR-223) (30 mg/kg, intraperitoneal, biweekly; Exiqon, Vedbaek, Denmark).
ASSAYS AND ANALYSIS. Proteins were isolated from cultured VSMCs and determined by Western blot analysis using antibodies for the insulin-like growth factor-1 receptor (IGF-1R), Akt, and phospho-Akt (Cell Signaling Technology, Danvers, Massachusetts).
Glyceraldehyde-3-phosphate dehydrogenase antibody was used as a loading control.
A fragment of the 3 0 -untranslated region (UTR) of IGF-1R mRNA, which contained the conserved miR-223 binding sequence with a firefly luciferase reporter, was transfected into HEK 293 cells. The cells were co-transfected with a vehicle, an empty plasmid (pDNR-CMV), and a plasmid expressing miR-223
(pmiR-223). Relative luciferase activity was measured.
VSMC proliferation was induced by platelet-derived growth factor (PDGF) (20 ng/ml) and determined by MTT assay and 5-ethynyl-2 0 -deoxyuridine assay (12) .
VSMC migration was determined by a modified Boyden chamber assay (12) , and VSMC apoptosis in cultured cells was measured by terminal deoxynucleotidyl transferase dUTP nick end labeling assay (12) . Blood Cell-Secreted miR-223 in Atherogenesis
The well-established leukocyte depletion and platelet depletion models in male wild-type C57BL/6 mice (3 months old) were used as described previously (13, 14) .
Atherosclerosis was induced in the aortas of apolipoprotein E (apoE) knockout male mice on a C57BL/6 background (The Jackson Laboratory, Bar
Harbor, Maine) by giving them a Western diet (13) .
Atherosclerotic lesions were measured by oil red O staining using en face preparation of whole aortas (13, 14) . Carotid artery balloon injury was induced in male Sprague-Dawley rats (230 to 300 g) as previously described (9) .
Right carotid artery ligation injury was induced in male wild-type C57BL/6 mice and age-matched miR-223 knockout mice as described in our previous study (15 Additional methodological details are described in the Online Appendix.
RESULTS
The results of the miRNA arrays demonstrated that miR-223 is the most abundant miRNA in platelets, leukocytes (monocytes), and blood microparticles from humans, mice, and rats. The 5 most abundant miRNAs in mice are shown in Online Table 1 . The origins of isolated microparticles from serum were discriminated by flow cytometry according to the expression of membrane-specific antigens. The majority of circulating microparticles were from platelets, followed by leukocytes and endothelial cells ( Figure 1A) ; the remainder (18%) were from other sources.
The expression levels of miRNA in mouse and rat serum were profiled by miRNA arrays. The top 5 miRNAs (Online Table 2 Table 2 .) Clearly, miR-223 was the most abundant miRNA in both animal and human serum.
To identify the distribution of extracellular miR-223 in blood, mouse serum was divided into 2 parts, supernatant and microparticle, as described previously (4, 5) , and the majority of the miR-223 was located in the latter ( Figure 1B) . To assess the stability of miR-223, the levels of miR-223 were determined immediately and 24 h later at 4 C. MicroRNA-223 in microparticles was very stable ( Figure 1C ), unlike the miR-223 outside the microparticles, which was not stable.
As shown in Figure 1D , it was difficult to find miR- Figure 2D ).
To further verify these findings with regard to miR-223 sources and mobility, we applied mouse models *p < 0.05 compared with control groups. Abbreviations as in Figure 1 .
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of leukocyte (neutrophil) or platelet depletion. As expected, the leukocytes or platelets in blood were successfully depleted by their special antibodies, as evidenced by the decreased numbers of these blood cells in mice ( Figures 2E and 2F ). Seven days after depletion, the serum and aortas from these mice were collected to measure the miR-223 levels, which were significantly decreased in mice with the depletion of leukocytes or platelets ( Figures 2G and 2H ).
The results suggest that blood cells are the major source of miR-223 in serum and vascular walls.
We also found that the serum levels of miR-223 from atherosclerotic apoE knockout mice and patients with atherosclerosis were significantly higher compared with the levels from normal control subjects ( Figure 3A) . Figures 3B to 3E , qRT-PCR results revealed that the miR-223 levels in balloon-injured rat arteries, ligation-injured mouse arteries, mouse atherosclerotic aortas, and human atherosclerotic arteries were significantly higher than those in matching normal control vessels. The successful rat carotid To increase the levels of miR-223, different concentrations of miR-223 mimic (1 to 30 nM) were used.
As shown in
We found that miR-223 had a strong negative effect on VSMC proliferation as determined by MTT ( Figure 4A) and 5-ethynyl-2 0 -deoxyuridine assay ( Figures 4B   and 4C) . Also, the miR-223 mimic inhibited the VSMC migration in a dose-dependent manner ( Figures 4D   and 4E ). In contrast, miR-223 overexpression significantly increased VSMC apoptosis ( Figures 4F and 4G ). Computational analysis suggested that human IGF-1R has a miR-223 binding site in its 3 0 -UTR, which is conserved in mice, rats, and humans ( Figure 5A ).
IGF-1R is thus a potential direct target gene in VSMCs.
To test this, the miR-223 mimic was transfected into VSMCs, and the IGF-1R expression was determined at both the protein and mRNA levels. The expression of IGF-1R was down-regulated in VSMCs ( Figures 5B to 5D ).
To further confirm that miR-223 is able to directly bind to IGF-1R and inhibit its expression, a fragment shown by the decreased expression of p-Akt ( Figures 5H and 5I ).
To test miR-223 effects on atherosclerosis, we applied a well-established mouse atherosclerosis model, in which atherosclerotic lesions were induced in apoE knockout mice by a Western diet. We confirmed that LN-anti-miR-223 (30 mg/kg), given both intravenously (tail vein) (Online Figures 1 and 2) or intraperitoneally ( Figures 6A and 6B ) biweekly could successfully knock down the miR-223 both in serum and vascular walls. We thus applied an intraperitoneal approach in this study. Our results demonstrated that miR-223 inhibition significantly increased atherogenesis, as shown by the increased atherosclerotic area determined via oil red O staining ( Figures 6C and 6D) . Figures 6E and 6F) . 
